Zura Bio (NASDAQ:ZURA) Shares Down 7.2% – Here’s Why

Zura Bio Limited (NASDAQ:ZURA) traded down 7.2% on Wednesday . The stock traded as low as $5.71 and last traded at $5.6860. 516,569 shares changed hands during trading, a decline of 44% from the average daily volume of 920,024 shares. The stock had previously closed at $6.13.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ZURA shares. Wedbush raised their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Guggenheim raised their target price on Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. William Blair began coverage on Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating for the company. Finally, Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Zura Bio Price Performance

The company has a market capitalization of $519.40 million, a PE ratio of -4.80 and a beta of -0.02. The company has a 50-day moving average of $5.61 and a two-hundred day moving average of $5.36.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) EPS for the quarter. As a group, research analysts anticipate that Zura Bio Limited will post -0.81 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in Zura Bio during the second quarter valued at approximately $28,000. Allworth Financial LP purchased a new stake in shares of Zura Bio in the fourth quarter worth $30,000. Scientech Research LLC purchased a new stake in shares of Zura Bio in the third quarter worth $45,000. AQR Capital Management LLC bought a new stake in shares of Zura Bio during the 1st quarter valued at $72,000. Finally, Bank of America Corp DE raised its position in shares of Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the period. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.